2 years ago

Inoviv Secures Funding from Hoxton Ventures and Foresight Group to Accelerate Biomarker Development

  • Inoviv, a London-based biomarker development company, has raised an undisclosed amount of funding from Hoxton Ventures and Foresight Group

  • The company plans to use the funds to expand its commercial activities, extend R&D capacity, and accelerate the development and approval of life-changing therapeutics

  • Inoviv offers solutions in hybrid assays that allow multiplexing of previously immeasurable biomarkers and rapid standards development to support quantitative workflows.

      • ProblemHealthcare

      "Accelerating clinical development and regulatory approval for precision biomarkers in the global pharmaceutical research community."

      Solution

      "Developing hybrid assays for multiplexing biomarkers, rapid standards development, and GLP/GCP accredited laboratories to provide definitive, fully quantitative data for pharmaceutical companies."

      Covered on